TO: ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS

FROM: PROTOCOL SECTION

DATE: MARCH 9, 2020

RE: PROTOCOL NRG-GY007-- PROTOCOL AMENDMENT 8

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCI Version: February 28, 2020
Study Chair: Charles N. Landen, Jr. M.D., 434-243-6131, Email: C13nj@hscmail.mcc.virginia.edu

The NCI Central Institutional Review Board (CIRB) has approved this protocol amendment. Protocol documents can be obtained from the CTSU website.

IRB Review Recommendation:
(X) Expedited review per 45 CFR 46.110 and 21 CFR 56.110
( ) Full board review

CIRB sites must have Amendment 8 (PVD February 28, 2020) locally implemented within 30 days of notification (posting on the CTSU website).

Sites not using the NCI Central Institutional Review Board (CIRB) as their IRB of record should submit Amendment 8 to the local IRB/IRB of record for review and approval. Per CTMB Guidelines, amendments must be submitted and approved by local IRBs within 90 days of this broadcast. Sites must submit their IRB approvals for this amendment to the CTSU.